总合成 (-) -spirotryprostatin B:合成和相关研究
Christiane Marti1, Erick M Carreira
1Laboratorium für Organische Chemie der ETH-Zürich, HCI H 335, Wolfgang Pauli Strasse 10, CH-8093 Zurich, Switzerland.
Journal of the American Chemical Society
|August 11, 2005
概括
研究人员实现了细胞静止性化物spirotryprostatin B的总合成. 一个关键的MgI2介导反应迅速组装了螺旋质素核,使得模拟合成.
科学领域:
- 有机化学 有机化学
- 药用化学 医学化学
- 合成化学 合成化学
背景情况:
- 螺旋素B是一种细胞静态化物,具有复杂的螺旋[pyrrolidine-3,3'-oxindole]结构.
- 开发高效的合成途径对于获取复杂的自然产品及其生物评估类型至关重要.
研究的目的:
- 为了描述螺旋质素B的总合成,B.
- 建立一种合成策略,允许轻松进行模拟合成和结构-活性关系 (SAR) 研究.
主要方法:
- 在spiro[cyclopropane-1,3'-oxindole]和aldimine之间进行化 (MgI2) 介导的环膨胀反应的应用.
- 使用Julia-Kocieński的olefination的一个关键的阿尔代前体安装 prenyl侧链.
主要成果:
- 顺利完成了螺旋质素B的总合成.
- 通过关键环膨胀反应快速组装核心螺旋质前列腺素结构.
- 效率高的安装 prenyl 侧链,促进模拟合成.
结论:
- 开发的合成途径提供了对spirotryprostatin B及其类似物的获取.
- 该策略适用于SAR研究,有助于发现新的治疗剂.
- 关键的MgI2介导反应是构建复杂的螺旋氧醇类化合物的强大工具.
相关概念视频
Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...


